FDA approves Array's drug combo to treat melanoma

Array BioPharma Inc. (NASDAQ:ARRY) said FDA approved Braftovi encorafenib in combination with Mektovi binimetinib to treat BRAF V600 mutation-positive unresectable or metastatic melanoma. The company said the combo is now available, but declined to provide a wholesale acquisition cost (WAC).

In February, Array reported that the combo significantly improved median overall survival (OS) compared with BRAF inhibitor Zelboraf vemurafenib in the Phase III COLUMBUS trial (see "Array Reports Phase III OS Data For Binimetinib Plus Encorafenib in Melanoma")...